Dynamic Changes in the Extracellular Matrix in Primary, Metastatic, and Recurrent Ovarian Cancers

Arkadiusz Gertych & Sandra Orsulic · 2022-11-25

Cancer-associated fibroblasts (CAFs) and their extracellular matrix are active participants in cancer progression. While it is known that functionally different subpopulations of CAFs co-exist in ovarian cancer, it is unclear whether certain CAF subsets are enriched during metastatic progression and/or chemotherapy. Using computational image analyses of patient-matched primary high-grade serous ovarian carcinomas, synchronous pre-chemotherapy metastases, and metachronous post-chemotherapy metastases from 42 patients, we documented the dynamic spatiotemporal changes in the extracellular matrix, fibroblasts, epithelial cells, immune cells, and CAF subsets expressing different extracellular matrix components. Among the different CAF subsets, COL11A1+ CAFs were associated with linearized collagen fibers and exhibited the greatest enrichment in pre- and post-chemotherapy metastases compared to matched primary tumors. Although pre- and post-chemotherapy metastases were associated with increased CD8+ T cell infiltration, the infiltrate was not always evenly distributed between the stroma and cancer cells, leading to an increased frequency of the immune-excluded phenotype where the majority of CD8+ T cells are present in the tumor stroma but absent from the tumor parenchyma. Overall, most of the differences in the tumor microenvironment were observed between primary tumors and metastases, while fewer differences were observed between pre- and post-treatment metastases. These data suggest that the tumor microenvironment is largely determined by the primary vs. metastatic location of the tumor while chemotherapy does not have a significant impact on the host microenvironment.

Journal
Cells
Funding
Precancer Niche Formation in the Fallopian TubeCancer-Associated Fibroblasts Alter the Composition of B cells in Solid MalignanciesUCLA Clinical and Translational Science InstituteClinical Protocol and Data Management (CPDM)Cancer-Associated Fibroblasts Alter the Composition of B cells in Solid MalignanciesUCLA Clinical and Translational Science InstituteUnited States Department of Veterans Affairs Grant VA-ORD I01 BX004974United States Department of Veterans Affairs Grant NIH R01 CA208753United States Department of Veterans Affairs Grant No. W81XWH2210631United States Department of Veterans Affairs Grant UL1TR00188United States Department of Veterans Affairs Grant no.07/010/SDU/10-21-01Office of the Assistant Secretary of Defense for Health Affairs Grant VA-ORD I01 BX004974Office of the Assistant Secretary of Defense for Health Affairs Grant NIH R01 CA208753Office of the Assistant Secretary of Defense for Health Affairs Grant No. W81XWH2210631Office of the Assistant Secretary of Defense for Health Affairs Grant UL1TR00188Office of the Assistant Secretary of Defense for Health Affairs Grant no.07/010/SDU/10-21-01Iris Cantor-UCLA Women’s Health Center/UCLA National Center of Excellence Grant VA-ORD I01 BX004974Iris Cantor-UCLA Women’s Health Center/UCLA National Center of Excellence in Women’s Health Pilot Research Project NCATS UCLA CTSI Grant NIH R01 CA208753Iris Cantor-UCLA Women’s Health Center/UCLA National Center of Excellence in Women’s Health Pilot Research Project NCATS UCLA CTSI Grant No. W81XWH2210631Iris Cantor-UCLA Women’s Health Center/UCLA National Center of Excellence Grant UL1TR00188Iris Cantor-UCLA Women’s Health Center/UCLA National Center of Excellence in Women’s Health Pilot Research Project NCATS UCLA CTSI Grant no.07/010/SDU/10-21-01Sandy Rollman Ovarian Cancer Foundation Grant VA-ORD I01 BX004974Sandy Rollman Ovarian Cancer Foundation Grant NIH R01 CA208753Sandy Rollman Ovarian Cancer Foundation Grant No. W81XWH2210631Sandy Rollman Ovarian Cancer Foundation Grant UL1TR00188Sandy Rollman Ovarian Cancer Foundation Grant no.07/010/SDU/10-21-01Mary Kay Foundation Grant VA-ORD I01 BX004974Mary Kay Foundation Grant NIH R01 CA208753Mary Kay Foundation Grant No. W81XWH2210631Mary Kay Foundation Grant UL1TR00188Mary Kay Foundation Grant no.07/010/SDU/10-21-01Annenberg Foundation Grant VA-ORD I01 BX004974Annenberg Foundation. Grant NIH R01 CA208753Annenberg Foundation. Grant No. W81XWH2210631Annenberg Foundation Grant UL1TR00188Annenberg Foundation. Grant no.07/010/SDU/10-21-01Silesian University of Technology Grant VA-ORD I01 BX004974Silesian University of Technology Grant NIH R01 CA208753Silesian University of Technology Grant No. W81XWH2210631Silesian University of Technology Grant UL1TR00188Silesian University of Technology Grant no.07/010/SDU/10-21-01

NCI NIH HHS

P30 CA016042

NCATS NIH HHS

UL1 TR001881